ACTG 219: PEDIATRIC LATE OUTCOMES PROTOCOL

ACTG 219：儿科晚期结果方案

• 批准号: 7377388
• 负责人: THOMAS H BELHORN
• 金额: $ 2.21万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7377388
• 关键词: ACTG; 219; PEDIATRIC; LATE; OUTCOMES

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is looking for any long-term effects of drug therapy on growth, development, long-term survival, and quality of life. The purpose of this study is to follow children and teenagers who are or have been in pediatric ACTG research studies. This includes all babies born to human immunodeficiency virus (HIV) infected mothers who were enrolled in an ACTG drug study when they were pregnant, infants or children who received anti-HIV vaccines, and children and teenagers enrolled in the Long Term Survivors study (LTS) sponsored by the Pediatric AIDS Foundation. All children will be followed until their 21st birthday.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。这项研究正在寻找药物治疗对生长、发育、长期生存和生活质量的长期影响。本研究的目的是追踪正在或曾经参与儿科 ACTG 研究的儿童和青少年。这包括怀孕时参加 ACTG 药物研究的感染人类免疫缺陷病毒 (HIV) 的母亲所生的所有婴儿、接受抗 HIV 疫苗的婴儿或儿童，以及参加长期幸存者研究 (LTS) 的儿童和青少年。 ）由儿科艾滋病基金会赞助。所有儿童都将受到跟踪直至其 21 岁生日。